{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T23:57:19Z","timestamp":1789257439054,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Apixaban is a non-vitamin K antagonist oral anticoagulant (NOACs) recently emerged as an effective alternative to conventional vitamin K antagonists (VKAs) in the treatment of several thromboembolic disorders. However, in case of overdose or in patients requiring emergency surgery there is a high bleeding rate and severe adverse side effects due to the absence of an antidote. There is promising data from <jats:italic>in vitro<\/jats:italic> and clinical studies, that certain antithrombotic agents (that is Rivaroxaban and Ticagrelor) have been successfully removed by the extracorporeal hemoadsorption therapy CytoSorb. Here, we present the case of a patient successfully treated with CytoSorb as a kind of antidote to enable emergency surgery for bilateral nephrostomy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 82-year-old Caucasian man was admitted to the Emergency Room with acute kidney injury (AKI) in the context of severe bilateral hydroureteronephrosis. The patient\u2019s medical history included chronic obstructive pulmonary disease, arterial hypertension, atrial fibrillation (anticoagulated with Apixaban) and a locally advanced prostate adenocarcinoma treated with trans-ureteral resection of the bladder and radiotherapy in the previous months. The indication for a bilateral nephrostomy could not be considered immediately given the major bleeding risk due to Apixaban, which was discontinued and replaced with calciparin. After 36\u00a0hours of continuous renal replacement therapy (CRRT), the Apixaban blood level was still elevated and it was decided to install CytoSorb into the running CRRT to accelerate the drug clearance. After 2\u00a0hours 30\u00a0minutes, there was good reduction of Apixaban from 139 to 72\u00a0ng\/ml (reduction rate of 48.2%) registered, and this allowed for an easy placement of bilateral nephrostomies without complications. Four days after surgery renal function parameters further normalized, the patient did not require additional dialysis treatments and Apixaban therapy was prescribed again once the patient returned home.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this case we report the findings of a patient with post-renal AKI requiring emergency nephrostomy placement while on chronic anticoagulation with Apixaban therapy. Combined treatment with CRRT and CytoSorb was associated with the rapid and effective removal of Apixaban allowing for prompt and urgent surgery while simultaneously ensuring the low risk of bleeding as well as an uneventful post-operative course.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-03949-3","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:02:04Z","timestamp":1688688124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Extracorporeal hemoadsorption therapy as a potential therapeutic option for rapid removal of Apixaban in high risk-surgical patients: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Vittorio","family":"Dalmastri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Minerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Ballarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Grammatico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Todeschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilia Maria","family":"Pizzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Silingardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"La Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"3949_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/europace\/euv309","volume":"17","author":"H Heidbuchel","year":"2015","unstructured":"Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467\u2013507.","journal-title":"Europace"},{"key":"3949_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/1753944717714921","volume":"11","author":"AGG Turpie","year":"2017","unstructured":"Turpie AGG, Purdham D, Ciaccia A. Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment. Ther Adv Cardiovasc Dis. 2017;11:243\u201356.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"3949_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","volume":"58","author":"W Byon","year":"2019","unstructured":"Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. 2019;58:1265\u201379.","journal-title":"Clin Pharmacokinet"},{"key":"3949_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/jcph.628","volume":"56","author":"X Wang","year":"2016","unstructured":"Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56:628\u201336.","journal-title":"J Clin Pharmacol"},{"key":"3949_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000484923","volume":"45","author":"A Koertge","year":"2018","unstructured":"Koertge A, Wasserkort R, Wild T. Extracorporeal hemoperfusion as a potential therapeutic option for critical accumulation of rivaroxaban. Blood Purif. 2018;45:126\u20138.","journal-title":"Blood Purif"},{"key":"3949_CR6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s12055-021-01183-4","volume":"37","author":"B Kr\u00fcger","year":"2021","unstructured":"Kr\u00fcger B, Renner T, Van Hemelrijck M, Sromicki J, Ouda A, Mestres CA. The effect of hemoadsorption on rivaroxaban blood plasma concentration in emergency cardiac surgery. Indian J Thorac Cardiovasc Surg. 2021;37:680\u20133.","journal-title":"Indian J Thorac Cardiovasc Surg"},{"key":"3949_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.athoracsur.2018.12.032","volume":"108","author":"K Hassan","year":"2019","unstructured":"Hassan K, Kannmacher J, Wohlmuth P, Budde U, Schmoeckel M, Geidel S. Cytosorb adsorption during emergency cardiac operations in patients at high risk of bleeding. Ann Thorac Surg. 2019;108:45\u201351.","journal-title":"Ann Thorac Surg"},{"key":"3949_CR8","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1177\/0267659120967827","volume":"36","author":"V Mendes","year":"2021","unstructured":"Mendes V, Colombier S, Verdy F, Bechtold X, Schlaepfer P, Scala E, et al. Cytosorb\u00ae hemoadsorption of apixaban during emergent cardio-pulmonary bypass: a case report. Perfusion. 2021;36:873\u20135.","journal-title":"Perfusion"},{"key":"3949_CR9","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1053\/j.jvca.2022.01.038","volume":"36","author":"H R\u00f8ed-Undlien","year":"2022","unstructured":"R\u00f8ed-Undlien H, Schultz NH, Lunnan A, Husebr\u00e5ten IM, Wollmann BM, Molden E, et al. In vitro apixaban removal by cytosorb whole blood adsorber: an experimental study. J Cardiothorac Vasc Anesth. 2022;36:1636\u201344.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"3949_CR10","unstructured":"Bristol-Myers Squibb, Pfizer EEIG. EU summary of product characteristics: Eliquis (apixaban tablets). 2018. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf. Accessed 19 Nov 2021."},{"key":"3949_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.bja.2017.11.082","volume":"120","author":"JW Eikelboom","year":"2018","unstructured":"Eikelboom JW, Kozek-Langenecker S, Exadaktylos A, Batorova A, Boda Z, Christory F, et al. Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. Br J Anaesth. 2018;120:645\u201356.","journal-title":"Br J Anaesth"},{"key":"3949_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jhep.2014.03.026","volume":"61","author":"S Russmann","year":"2014","unstructured":"Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, H\u00fcrlimann S, et al. Rivaroxaban postmarketing risk of liver injury. J Hepatol. 2014;61:293\u2013300.","journal-title":"J Hepatol"},{"key":"3949_CR13","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.3390\/jcm10215182","volume":"10","author":"K Ocskay","year":"2021","unstructured":"Ocskay K, Tomescu D, Faltlhauser A, Jacob D, Friesecke S, Malbrain M, et al. Hemoadsorption in \u2018liver indication\u2019-analysis of 109 patients\u2019 data from the CytoSorb international registry. J Clin Med. 2021;10:5182.","journal-title":"J Clin Med"},{"key":"3949_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000455064","volume":"44","author":"S B\u00fcttner","year":"2017","unstructured":"B\u00fcttner S, Patyna S, Koch B, Finkelmeier F, Geiger H, Sarrazin C, et al. Application of hemoadsorption in a case of liver cirrhosis and alcohol-related steatohepatitis with preexisting hepatitis C infection. Blood Purif. 2017;44:30\u20131.","journal-title":"Blood Purif"},{"key":"3949_CR15","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1159\/000505899","volume":"49","author":"O Dilken","year":"2020","unstructured":"Dilken O, Ince C, van der Hoven B, Thijsse S, Ormskerk P, de Geus HRH. Successful reduction of creatine kinase and myoglobin levels in severe rhabdomyolysis using extracorporeal blood purification (CytoSorb). Blood Purif. 2020;49:743\u20137.","journal-title":"Blood Purif"},{"key":"3949_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13054-021-03468-x","volume":"25","author":"C Scharf","year":"2021","unstructured":"Scharf C, Liebchen U, Paal M, Irlbeck M, Zoller M, Schroeder I. Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis. Crit Care. 2021;25:41.","journal-title":"Crit Care"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03949-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-03949-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03949-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:02:07Z","timestamp":1688688127000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-03949-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3949"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-03949-3","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"assertion":[{"value":"16 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of the details of her medical case and any accompanying images. The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"283"}}